RE: Take off
"""-----INNEXUS BIOTECHNOLOGY INC ( IXS.V )-----"""size=4>color=RED>
MAJOR NEWS----InNexus says study shows DXL625 kills tumour cellssize=4> INNEXUS BIOTECHNOLOGY ( TRADING JUST AT 0.35 CENTS ) ANNOUNCES PRELIMINARY RESULTS OF ANIMAL STUDY COMPARING CANCER KILLING ACTIVITY OF ITS DXL625 (CD20) TREATMENT FOR NON-HODGKIN'S LYMPHOMA WITH LEADING MARKETED PRODUCT
UP 200% AND RISING FAST,,HEDGE FUNDS ARE BUYING LARGEsize=4>color=RED> https://stockcharts.com/h-sc/ui?s=ixs.V&p=D&b=5&g=0&id=p95524307080 -PENDING NEWS OF 30 MILLION ROYALTY @ PRICE OF $ 1.01 GANA MAKE THIS STOCK FLY -DXL 625 is IXS's first drug offering that enhances or betters Rituxan a $2.06 Billion a year drug. -The animal testing results show that DXL 625 is more effective than Rituxan (remember a $2 Billion drug). -The CEO has indicated a 2nd drug is in the works and another $30 Million from Royalty will be soon be available to company @ price of $ 1.01 per share
Show me another Biotech with this much going for it with such a low market cap. This thing is going to take off.------------- Recommandation *STRONG BUY* --------------size=4> THIS STOCK IS AT THE TOP OF THE PHARMACEUTICAL WORLD - PLACE YOUR BETS BUY LOW BEFORE HEADING TO DA MOOOOOOOOOON